2024
Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimod
2019
Successful application of prime and pull strategy for a therapeutic HSV vaccine
Bernstein DI, Cardin RD, Bravo FJ, Awasthi S, Lu P, Pullum DA, Dixon DA, Iwasaki A, Friedman HM. Successful application of prime and pull strategy for a therapeutic HSV vaccine. Npj Vaccines 2019, 4: 33. PMID: 31396405, PMCID: PMC6671986, DOI: 10.1038/s41541-019-0129-1.Peer-Reviewed Original ResearchHerpes simplex virus type 2PBS control groupRecurrent sheddingControl groupVaginal HSV-2 infectionSimplex virus type 2Herpes simplex virus vaccineRecurrent HSV diseaseTherapeutic HSV vaccinesHSV-2 infectionCombinations of vaccinesGuinea pig modelVirus type 2Imiquimod groupHSV diseaseHSV vaccineRecurrent diseaseRecurrent lesionsRecurrent HSVVaccinated groupGlycoprotein vaccineTrivalent vaccineImmune cellsVirus vaccineGenital tract